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Summary.-The metal complexes Pd(MP)2 2H20, Pt(MP)22H20 (MPH=6-mercap-
topurine), Pt(AMP)2-3H20 and Pd3(AMP)4C12(AMPH)-4H2O (AMPH=thioguanine)
have been isolated. They were screened for anti-tumour activity in the L-1210 lym-
phoid leukaemia test system in mice. All 4 show marked anti-tumour activity, the
complex Pt(AMP)2 *3H20 giving a T/C of 185 at the optimum dosage. However, the
anti-tumour activity of the metal complexes is somewhat less than that shown by the
parent purines under the same conditions.
THE effectiveness of 6-mercaptopurine
(I; MPH) and related compounds in the
treatment of leukaemias was reported in
1954 (Miner) and the 2-amino derivative,
thioguanine (II; AMPH) has been widely
used in the treatment of various types of
cancer. Consequently, as part of our study
of metal chelates* as potential anti-
cancer agents, we havepreparedpalladium
(Pd) and platinum (Pt) complexes ofthese
purines and had them screened in the
LI210 lymphoid leukaemia test system.
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The formation constants of the nickel
(II), cobalt(II), lead(II), and zinc(II)
complexes of6-mercaptopurine were deter-
mined by Cheney et al. (1959) and the iso-
lation ofthe metal complexes Met(MP)2 n-
H20 (Met=Co, Ni, Cd; n 1, 2, 5, resp.)
was reported by Ghosh and Chatterjee
(1964). Several anionic complexes of
cobalt(III) have also been reported (Bri-
gando and Colaitis, 1967).
Kirschner et al. (1966) reported that the
complexes Na2[Pt(MP)2C14]2H20 and Na2-
[Pd(MP)2CI2] *H20 displayed anti-cancer
activity. The platinum(IV) complex in-
duced a decrease in tumour weight of
29% at the optimum dosage in the
Sarcoma 180 test system in mice but
showed no significant activity in the
Adenocarcinoma 755 test system. The
palladium(II) complex displayed activity
in both test systems: a maximum tumour
weight decrease of18% in the 180 Sarcoma
test screen and of 33%0 in the Adenocarci-
noma 755 test screen.
MATERIALS AND METHODS
WVe have prepared Pd(IJ) and Pt(II)
conmplexes of 6-mercaptopurine and thio-
guanine (2-amino-6-mercaptopurine). The 6-
mercaptopurine complexes have the stoi-
cheiometrv Met(MP)2 *2H20 (Met=Pd, Pt),
while the Pt complex of thioguanine has the
formula Pt(AMP)2 3H20. The structure of
these complexes is open to question. The
deprotonated purine may act as a chelating
agent, coordinating via the sulphur and the
* A metal chelate is a metal complex in which one or more ligands (attached groups) are bound to the
metal atom via two or more donor atoms. A chelating agent is a ligand which can bind to a metal atom in
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nitrogen at position number 7 in the imidazole
ring to yield the ci8 square-planar monomeric
complex (III). The cis configuration is
favoured relative to the trans configuration
for transition metal complexes of thiolo
ligands (Das et al., 1974). On the other
hand, since imidazole nitrogen is a poor
donor, it is possible that the deprotonated
purine behaves as a unidentate ligand, being
bound to the metal atom viathe sulphur atom
only, yielding the polymeric thiolo-bridged
complex (IV; R==purine moiety). Any other
structure, involving nitrogen bonding, is
unlikely in view of the high affinity of Pd(II)
and Pt(II) for sulphur bonding.
(IfI; Met = Pd or Pt; X = H or NH2)
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The complex obtained from the reaction of
Pd(II) with thioguanine has the stoicheio-
metry Pd3(AMP)4Cl2(AMPH)*4H2O. It seems
unlikely that this substance is a mixture,
since products having essentially the same
analysis were obtained from 3 different
preparations. A structure for this complex
cannot be postulated with any degree of
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certainty, but the polymeric structure (V)
is a possibility.
The metal complexes were screened for
anti-tumour activity in the lymphoid leu-
kaemia L1210test system andtheresults were
compared with those for the purines under
similar conditions.
Preparation of Metal Chelates
Bis(6-purinethiolo)palladium(JI) Dihydrate.
-A solution of 0 7 g potassium tetrachloro-
palladate(II) 30 ml in water was added to a
suspension of0 7 g finely powdered 6-mercap-
topurine monohydrate (Aldrich Chemical Co.,
Milwaukee) in 50 ml ethanol. The mixture
was heated on the steam bath for 30 min
with occasional stirring. The resultant deposit
of the yellow palladium complex was separa-
ted by filtration, washed with hot ethanol,
and dried in vacuo over silica gel. Yield, 0-85 g
(Found: C, 27-3; H, 2-0; N, 25-4; Pd, 23.9%.
Calcd. for C1oH,oN8O2PdS2: C, 27-0; H, 2-3;
N, 25-2; Pd, 24-1%).
Bis(6-purinethiolo)platinum(ll1) Dihydrate.
-A solution of 0-95 g potassium tetrachloro-
platinate(II) in 30 ml water was added to a
suspension of 0 75 g finely powdered 6-mer-
captopurine (Aldrich) in 50 ml ethanol. The
mixture was heated on the steam bath for
30 min and the resultant reddish-brown
platinum complex was filtered off, washed
with hot ethanol, and dried in vacuo over
silica gel. Yield, 1-0 g (Found: C, 23-7; H,
1-7; N, 20-9; Pt, 36-5%. Calcd. for
CjOHjON8O2PtS2: C, 22-5; H, 1-9; N, 21-0;
Pt, 36-5%).
Dichlorotetrakis(2 - aminopurinethiolo) - 2 -
amino-6-mercaptopurinetripalladium(II) Tet-
rahydrate.-Asolutionof 1 2gpotassiumtetra-
chloropalladate in 50 ml water was added to a
suspension of 1-0 g finely powdered 2-amino-
6-mercaptopurine (Aldrich) in 50 ml ethanol.
The mixture was heated on the steam bath
for 90 min with stirring. The deposite oflight
brown palladium complex was filtered off,
washed with hot ethanol, and dried in vacuo
over silica gel. Yield, 1-5 g. (Found, on
different preparations: C, 23-2, 22-7; H, 1-9,
2-0; Cl, 6-5; N, 26-5, 25-5; Pd, 23-3, 24.0%.
Calcd. for C25H30Cl2N2504Pd3C12: C, 23-2;
H, 2-3; Cl, 5-6; N, 27-0; Pd, 24.6%).
Bis(2 - amino - 6 -purinethiolo)platinum(II)
Trihydrate.-A solution of 1-0 g potassium
tetrachloroplatinate(II) in 30 ml water was
added to a suspension of 0-75 g finely pow-
dered 2-amino-6-mercaptopurine (Aldrich) in
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50 ml ethanol. The mixture was heated on the
steam bath for 2 h with continuous stirring.
The resulting deep yellow platinum complex
was separated by filtration, washed with
ethanol, and dried in vacuo over silica gel;
Yield, 0-85 g (Found: C, 2058; H, 1-8; N, 23-5;
Pt, 334%. Calcd. for CjoH14NjoO3PtS3: C,
20'7; H, 2-4; N, 2441; Pt, 33-55%).
Analyses
Analyses for C, H, and N were carried out
by the Microanalytical Laboratory, School of
Chemistry, University of New South Wales.
Analyses for Pd and Pt were made by careful
ignition of the complex. For Pd, the metal
residue was allowed to cool in an atmosphere
of methanol vapour.
Screening of Compounds
The screening was carried out in labora-
tories associated with the U.S. National
Cancer Institute, viz. A. D. Little Inc.,
U.S.A., Southern Research Institute, U.S.A.,
and Institut Jules Bordet, Brussels, Belgium.
The screening was in accordance with the
screening protocol for lymphoid leukaemia
L1210 (Cancer Chemotherapy National Ser-
vice Centre, 1959). The animals used were
mice, weighing 18-22 g, of a single sex for
any one experimental group. The number of
animals in each test group and control group
was usually 6 (sometimes 3 or 10). The mice
were inoculated i.p. with 0-1 ml of diluted
ascitic fluid containing 105 cells of the
TABLE I.-Summary of screening data for
anti-tumour activity of the purines and
their metal chelates in the L1210 lym-
phoid-leukaemia test system in mice
under comparable conditions*
Dose
at
Dose
range T/C
Compound (mg/kg) Range
MPH.H20 8-510 96-180
Pd(MP)2.2H20 12 - 5-400 98-161
Pt(MP)2.2H20 25-400 96-135
AMPH 1-106 110-236
Pd3(AMP)4C12-
(AMPH).4H20 3 - 12-100 91-164
Pt(AMP)2.3H20 25-400 107-185
mm
Dose at T/C
max T/C (mg/
(mg/kg) kg)
255 510
50 200
400 25
53 1-8
6 25 100
400 25
* Interval between injections, 4 days; number of
injections, 2-4; evaluation at 30th day.
MPH=6-mercaptopurine.
AMPH=2-amino-6-mercaptopunine (thioguanine).
TABLE II.-Some typical results for anti-
tumour activity of the purines and their
metal chelates in the L1210 lymphoid-
lez'kaemia test system in mice
Compound
MPH.H20
Pd(MP)2.2H20
Pt(MP)2.2H20
AMPH
Pd3(AMP)4C12-
(AMPH) .4H20
Pt(AMP)2.3H20
No. of
injec-
tions
(4-day
inter-
vals)
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
2
2
4
2
4
2
4
4
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
Dose per
injection
(mg/kg)
510
255
128
32
16
8
200
100
50
25
12 -5
400
200
100
50
25
106
53
40
27
27
14
13
8
7
3 -5
1 -8
1
100
50
25
12 5
6-25
3-13
400
200
100
50
25
T/C
96, 104
180, 170
131, 131
102, 103
102, 105
106, 105
98
156, 140
161, 157
141, 117
138
135, 129
125, 107
104, 100
100, 98
96
118
236, 176
145
197
178
197
174
156
171
161, 147
143, 110
154
91, 114
153, 142
149, 146
149, 142
164
124
185, 146
156, 150
129, 126
128, 117
112, 107
lymphoid leukaemia L1210. On the next day,
the mice were injected i.p. with a suspension
ofthe compound being tested; for the purines
the vehicle was alkali diluted with saline and
for the metal complexes the vehicle was
saline with Tween-80. A total of 2-4, usually
3, injections were given at 4-day intervals.
Toxicity was evaluated as survival 5 days
after the injection, which was practically
100%.
The results of the screening were evaluated
after 30 days on the basis of survival. For
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the 105-cell inoculum in theL1210 leukaemia
screen, the mean day of death for untreated
control mice is usually between 8 and 11
days. The experiment was evaluated on Day
30 even if some animals were still alive on
that day. The T/C percentage was calculated
from the mean survival time of the test and
control mice. For example, if the mean sur-
vival time of the untreated control mice was
9-1 days and for the treated mice it was 12-8
days, then T/C was 140%.
RESULTS
A summary of the screening data is
given in Table I, and some typical results
are given in Table II. A T/C (Test
evaluation/Control evaluation x 100) of
100 means that the compound has no
effect in either decreasing or increasing
the tumour. A T/C. 125 was taken to
indicate significant anti-tumour activity.
DISCUSSION
From the data listed in Table I it can
be seen that all 4 metal complexes display
considerable anti-tumour activity. The
Pd complex of 6-mercaptopurine is almost
as effective as an anti-tumour agent as
6-mercaptopurine itself, whereas the act-
ivity of the Pt complex is considerably
less. On the other hand, the Pt complex of
thioguanine has a greater anti-tumour
activity than the Pd complex, though this
is considerably less than that ofthe purine.
It should be pointed out that higher
values ofT/C have been obtained for these
purines in the L1210 test system under
different testing conditions. For example,
a T/C of 337 has been obtained for
thioguanine at a dose level of 0 50 mg/kg
per injection with 32 daily injections and
evaluation on the 60th day. However, if
meaningful comparisons are to be made
for the relative anti-tumour activities of
the purines and their metal chelates, the
screening must be done under the same
conditions.
Since there is still some doubt about the
selectiveactionofpurinessuchas6-mercap-
topurine on tumour cells, it would be
pointless to speculate on the mode of
action of their Pd and Pt complexes.
The metal complexes are virtually
insoluble in all common solvents and are
non-toxic at doses up to 400 mg/kg. Their
anti-tumour activity, although appre-
ciable, appears to be significantly less
than that of their parent purines.
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